The role of host genetic factors in the pathogenesis and outcome of hepatitis B virus (HBV) infection is not well known.
Introduction
Hepatitis B virus (HBV) infection is a serious public health problem. 1 HBV infects more than 400 million people worldwide, and 75% of them are Asians. 2, 3 India harbors the second largest global pool of chronic HBV infection. 4 HBV causes a broad spectrum of diseases from subclinical infection to acute, fulminant and chronic infection. The majority of infection in the adulthood is self-limited, but 5-10% progress into chronic hepatitis. Several lines of evidence indicate that the dichotomy of HBV outcome is largely determined by the host immune response. We have also suspected a strong genetic reason for clustering of chronic HBV carrier in India because of its endogamous population structure. 5, 6 In addition, familial clustering of HBV infection has been shown in the Indian population. 7 HBV is a known noncytolytic hepatotropic virus. 8 Individuals with acute HBV infection who clear the virus elicit strong, polyclonal class 1-and II-restricted cell responses. In contrast, the cellular responses are weak and restricted in patients with chronic HBV infection. 8, 9 Thus, immune responses evoked against HBV-encoded antigens are responsible for the liver injury and the associated pathology in the HBV disease. The major histocompatibility complex (MHC) class II molecule function is essential for antibody response to hepatitis B surface antigen (HBsAg). The antibodies to HBsAg (anti-HBs) curtail the spread and clear the circulating virus particles. 10 The MHC class I molecule function is important for cytolytic elimination of HBVinfected hepatocytes. 8 Thus, HLA polymorphism is one of the major host determinants that can influence the susceptibility, severity and the outcome of HBV infection.
Tumor necrosis factor-a (TNF-a) is a chief proinflammatory cytokine. It is described as a potential type 1 immunoregulatory cytokine functionally different in modulating the detrimental type 1 immune response. 11 The level of cytokine production varies among individuals, and this may correlate with polymorphisms in the cytokine gene promoters. 12 Many single nucleotide polymorphisms are described in the promoter region of the TNF (NM_000594.2). [13] [14] [15] [16] These promoter polymorphisms are known to influence TNF-a transcription. 17, 18 TNF-a determines host cytolytic and noncytolytic antiviral response to HBV infection. 19 The cytolytic and noncytolytic control of HBV replication is mediated by TNF-a and interferon-g secreted by natural killer cells, natural killer T cells and CD8 þ cells.
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The aim of the present study was to ascertain the association of HLA polymorphisms and the five single nucleotide polymorphisms located near 5 0 of TNF (NM_000594.2:c. À238:G4A, À308:G4A, À857:C4T, À863:C4A, À1031:T4C) with the outcome of HBV infection in the South Indian population.
Results
There was a significant difference in median age between spontaneously recovered (SR) group (33.2 ± 9.1) and chronic-HBV (C-HBV) group (36.9±13.4; Po0.001). The gender ratio (female/male) was significantly different between SR group (4:146) and C-HBV group (36:101; Po0.001). Among the C-HBV carriers, 58.4% were positive for HBV DNA with the median viral load of 402.5 IU ml -1 (2-7 Â 10 7 IU ml -1 ). Of C-HBV carriers, 45 (32.8%) showed elevation of serum alanine transaminase levels with the median of 47 U l -1 (36-356 U l -1
). The histological activity index (HAI) was available for 27 chronic liver disease patients and a majority of them had HAI of p5, indicating mild liver disease except one patient (HAI 8/16). Hepatic fibrosis score (HFS) was available for 9 patients; a majority of them had mild fibrosis (HFS p2), one had HFS of 5/6 indicating severe liver disease and other one had indication of mild steatosis.
HLA polymorphism and HBV outcome No association of class I (A and B) MHC alleles were found between individuals with SR and C-HBV carriers after correction for multiple comparisons (data not shown). However, the allelic frequency (AF) of HLA-B*44 was higher in the C-HBV carriers than individuals with SR (18.07 vs 3.45%; odds ratio (OR) 6.23, 95% confidence interval (CI) 1.66-23.34, P ¼ 0.007).
The distribution of class II (DR) alleles and association with HBV outcome are shown in Table 1 . A significantly higher frequency of HLA-DRB1*07:01 was observed in patients with chronicity (57.83% of 83) compared with individuals with SR (24.71% of 85) after correction for multiple comparisons (OR 3.76, 95% CI 1.84-7.68, pco0.006). On the contrary, the allelic frequency of HLA-DRB1*03:01 was higher in the SR group (12.94% of 85) than the C-HBV group (1.2% of 83; OR 0.08; 0.003-0.64; P ¼ 0.007). None of the DQB1 alleles were associated with HBV outcome (data not shown).
TNF polymorphism and HBV outcome
Among the TNF polymorphisms only rs1800630 allele was found to be strongly associated with HBV outcome even after correcting for multiple comparison using permutation tests (P ¼ 0.006; data not shown). The frequency of TNF genotypes in the two groups did not violate Hardy-Weinberg equilibrium; data not shown).
Univariate analysis showed a significant association of rs1800630 genotypes with HBV outcome (pco0.01). We found a strong association between rs1800630 genotypes and HBV outcome in the codominant (OR ¼ 1.99, pco0.01) and in the dominant (OR ¼ 2.28, pco0.01) analyzing models after adjusting for age and sex (Table 2) . Likewise, univariate analysis revealed a trend between rs1799964 genotypes and HBV outcome (P ¼ 0.025). After adjusting for age and sex, rs1799964 genotypes showed a significant association with HBV outcome in the codominant (OR ¼ 1.57, pc ¼ 0.01) and the dominant (OR ¼ 2.21, pco0.01) analyzing models ( Table 2) .
Linkage disequilibrium coefficients among five TNF single-nucleotide polymorphisms are shown in Figure 1 . The frequencies of TNF haplotypes are shown in Table 3 . Among the six haplotypes, the second predominant TNF haplotype 2 (rs1799964C; rs1800630A; rs1799724C; rs1800629G; rs361525G) was associated with C-HBV infection (P ¼ 0.0004). This association is significant even after correction for multiple comparison using permutation test (pc ¼ 0.004; Table 3 ).
Differential association of TNF genotypes with HLA-DRB1*07:01 in chronic HBV outcome The frequency distributions of rs1800630 and rs1799964 genotypes in HLA-DRB1*07:01 individuals are shown in Table 4 . The frequency of rs1800630 genotypes was not significantly different between HLA-DRB1*07:01-positive and -negative individuals. The difference in the frequency of rs1799964 genotypes was found to be marginally significant between HLA-DRB1*07:01-positive and -negative individuals (P ¼ 0.05).
Discussion

HLA polymorphism and HBV outcome
Polymorphic changes within the MHC regions have been shown to influence the immune response against HBV infection. 23 Our study showed the association of predominant South Indian HLA class II allele (DRB1*07:01) with C-HBV outcome. This has important biological relevance because individuals who clear the HBV are known to elicit strong, polyclonal class I-and IIrestricted cell responses but the cellular responses are weak and restricted in patients with C-HBV infection. 8, 9 Our study revealed that HLA-B*44 and DRB1*03:01 alleles were associated with C-HBV and SR (P ¼ 0.007) outcomes, respectively. After adjusting for multiple comparisons, these alleles were not associated with HBV outcome. Besides, wide variations in the frequency distribution of these alleles are known to occur in the South Indian castes and tribes. 24, 25 We speculate that this variation may impact the epidemiology and outcome of HBV infection in the South Indian population. However, this requires study with larger sample size including various ethnic groups of the South Indian population.
HLA-DRB1*07:01 allele showed a strong association with C-HBV infection (pco0.006). The frequency distribution of this allele was also highest among the DRB1 alleles in our study population. This observation is concordant with an earlier study by Shankarkumar and Sridharan. 26 Our study also revealed that HBV infection of HLA-DRB1*07:01-positive individuals had a 3.8-fold higher risk of progression to chronicity. This OR is higher than what is normally seen (OR 1.2-2) in various genetic association studies. 27 Our study also independently replicated the association of HLA-DRB1*07 with persistent HBV infection as shown earlier by Almarri and Batchelor. 28 Furthermore, studies have shown the association of HLA-DRB1*07 with nonresponsiveness to HBV vaccination in various populations. [29] [30] [31] [32] We speculate that the strong association of HLA-DRB1*07:01 with chronicity could be either because of the inability of this allele to present epitopes effectively or because of the inheritance of certain markers linked to other important genes. This warrants further functional and genetic studies to identify the precise role of HLA-DRB1*07:01 with persistence of HBV infection. This finding may have an impact on the South Indian population as the frequency of HLA-DRB1*07 have been shown to be higher in this population. 26 Therefore, this observation is more pertinent to the South Indian population than populations where the frequency of this allele is low.
TNF polymorphism and HBV outcome TNF-a determines host cytolytic and noncytolytic antiviral response to HBV infection. 19 Among the TNF polymorphisms, only rs1800630 alleles showed a significant trend with the outcome of HBV infection (P ¼ 0.027; data not shown). In addition, the rs1800630 genotypes were associated with HBV outcome in the codominant and dominant analyzing models. We speculate that the ORs (1.99 and 2.28) of our study reflect the complex Mendelian trait (HBV disease outcome) and influence of several polymorphic genes on the outcome of HBV infection. 27 However, this association is consistent with the expected OR (1.2-2) that is commonly seen in genetic association studies. 27 According to Thursz, 27 an OR of 1.2-2 requires thousands of cases than hundreds for a valid genetic association studies. Considering this criterion, the potential drawback of our study could be the sample size, which was overcome by using permutation test. 33 Empirical P-values were obtained for 10 000 permutation that showed a strong association between rs1800630 polymorphism and the outcome of HBV infection (P ¼ 0.006). Our study also independently replicated the earlier findings of a Korean study and a Taiwanese study that showed an association of rs1800630 polymorphism with the outcome of HBV infection. 34, 35 This independent replication strengthens the association of rs1800630 polymorphism with HBV outcome.
We believe that the association of rs1800630 polymorphism with HBV outcome should have certain functional basis than serving as a mere marker. Hence, it is reasonable to propose that the TNF mutant A-allele (rs1800630) might lead to the production of low level of TNF-a resulting in C-HBV infection. Corroborating this notion, a functional study has shown that the rare variant of rs1800630 (A-allele) exhibited 31% lower transcriptional activity than the wild-type C-allele. 36 Recently, the TNF mutant A-allele has been shown to predict lower HBcAg-inducible TNF-a secretion and is also associated with chronicity. 35 We speculate that the transcriptional difference in rs1800630 promoter alleles influence pathogenesis and the outcome of HBV infection in the South Indian population. However, comprehensive functional studies are essential to unravel the underlying mechanism of rs1800630 polymorphism on the outcome of HBV infection.
We also found that rs1799964 polymorphism was associated with HBV outcome. Worldwide, the evidence for association of rs1799964 polymorphism with HBV outcome is highly limited. Till date, only one study has emphasized the importance of rs1799964 promoter wildtype allele-C and rs1800630 allele-A with prognosis of Associated with HBV outcome in the codominant (0.001) and dominant (0.002) analyzing models (refer Table 2 ).
c Associated with HBV outcome in the codominant (0.016) and dominant (0.005) analyzing models (refer Table 2 ).
fulminant hepatitis. 37 The other TNF promoter polymorphisms (rs361525, rs1800629 and rs1799724) that are known to influence TNF-a level were not associated with HBV outcome in this study. However, many studies have shown the association of these polymorphisms with diverse HBV outcomes. [37] [38] [39] [40] [41] The reason for this nonassociation in the South Indian population is presently not known.
As HLA and TNF are closely located in the same chromosome, linkage disequilibrium between these two genes can influence the outcome of HBV infection. To elicit this association, we performed a differential association analysis between TNF genotypes and HLA-DRB1*07:01 that were associated with HBV outcome among the C-HBV carriers. We found that the frequency of rs1799964 genotypes was marginally significant between HLA-DRB1*07:01-positive and -negative individuals (P ¼ 0.05). We speculate that rs1799964 genotypes and HLA-DRB1*07:01 may have an additive impact in determining the chronicity in the South Indian population.
In summary, the predominant South Indian HLA-DRB1*07:01 allele is strongly associated with C-HBV infection. The DRB1*07:01 allele and rs1799964 genotypes may have an additive effect in determining C-HBV infection. The TNF promoter allele associated with lower TNF-a plasma levels, that is, the presence of rs1800630A (C/A and A/A), is strongly associated with C-HBV infection. The rs1799964 promoter genotypes also significantly associated with the outcome of HBV infection. The TNF haplotype 2 (rs1799964C; rs1800630A; rs1799724C; rs1800629G; rs361525G) was strongly associated with C-HBV infection. Our findings suggest that MHC-class II polymorphisms and the TNF promoter polymorphisms governing the level of TNF-a are important population-specific host genetic factors that may determine the variable outcome of HBV infection. These findings may also provide insights into the molecular mechanism of HBV persistence and open novel therapeutic possibilities to overcome C-HBV infection.
Materials and methods
Power calculations
Power calculations were based on the following assumptions. The OR was fixed at 2.0 and power calculations were made under the log-additive model. Based on an earlier study, the frequency of TNF risk allele was at least 10% in the South Indian population. 42 Based on this assumption, a minimum of 140 samples in each group would be required for studying the association between TNF polymorphisms and HBV outcome with 80% power at 5% significance level.
At the time of design of our study, the only published Indian study showed HLA DRB1*15XX to have the strongest association with HBV outcome in the Western Indian population. 43 The frequency distribution of this allele was 20% in the random South Indian population. 26 Based on this assumption, a minimum of 90 samples in each group would be required for studying the association between HLA polymorphism and the outcome of HBV infection with 80% power at 5% significance level.
Subjects and study design
In this case-control study, subjects were enrolled over a period of 1 year and 8 months (August 2005 to April 2007) from the four South Indian states (Tamil Nadu, Andhra Pradesh, Kerala and Karnataka) at Christian Medical College and Hospital. The HBV-exposed and SR individuals were recruited from volunteer/replacement blood donors. C-HBV carriers were referred from liver clinic of this hospital as a part of routine molecular evaluation of chronic liver diseases. The study was explained to all participants and a written consent was obtained. Institutional Review Board approval was obtained before the commencement of the study. Subjects with human immunodeficiency virus, hepatitis C virus co-infections, alcoholic liver disease, autoimmune hepatitis, primary biliary cirrhosis, Wilson's disease and hematological malignancies were excluded from the study.
Stratification of subjects
The subjects were stratified based on the HBV serological and molecular markers into the following groups. 
Serology
The serological screening of HBV was performed for the following markers: HBsAg (ETI-MAK-4 HBsAg Enzyme Immunoassay Kit, Diasorin, Saluggia, Italy), Anti-HBc IgG (ETI-AB-COREK plus, total Anti-HBc Enzyme Immunoassay Kit, Diasorin) and anti-HBs (BIO-RAD MONOLISA ANTI-HBs 3.0 3, Bio-Rad, Hercules, CA, USA) to stratify the subjects into three groups. Antibody screening for HIV (GENSCREEN PLUS HIV Ag-Ab 3, Bio-Rad and HCV (ORTHO HCV 3.0 ELISA, Ortho-Clinical Diagnostics Inc., Raritan, NJ, USA) were also performed to rule out co-infection.
Detection of HBV DNA Plasma DNA was extracted using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) and HBV DNA detection were performed using real-time PCR (Artus HBV RG PCR Kit; Qiagen).
Genomic DNA extraction Genomic DNA was extracted from the buffy coat by an earlier reported salting-out procedure. 44 
HLA typing
The low-resolution typing of class I (A and B) and II (DR and DQ) alleles were performed using commercial assay by AllSet þ Gold SSP (Invitrogen, Brown Deer, WI, USA). The high-resolution typing was performed for class I (B*44) and class II (DRB1*07 and DRB1*03) alleles that showed association with HBV outcome using Olerup SSP AB (Saltsjobaden, Sweden). Manufacturer's instructions were followed. To ensure the validity of HLA typing, 5% of the samples were retyped.
Typing of TNF promoter polymorphisms The rs361525 polymorphism was resolved by amplification refractory mutation system-PCR (ARMS-PCR). 45 To validate the ARMS-PCR results, at least 10% of the samples were typed by PCR-restriction fragment length polymorphism. 46 The rs1800629 polymorphism was identified by PCRrestriction fragment length polymorphism as described earlier. 47 The results of this method was validated by typing 410% of the samples using tetra-primer ARMS-PCR method. 48 The rs1799724, rs1800630 and rs1799964 polymorphisms were identified by sequence-specific primer-PCR. 49 To validate the sequence-specific primer-PCR results, 5% of samples were retyped.
Amplification and digestions were performed in a Perkin Elmer GeneAmp PCR system 2700 (Roche diagnostic systems, CA, USA). For all polymorphic sites, negative control (PCR grade water) and previously genotyped samples as controls were included to rule out contamination and validation of results respectively. All PCR products were separated on 2% agarose gels (Sigma, St Louis, MO, USA), stained with ethidium bromide (0.5 mg ml -1 ), and visualized by ultraviolet radiation using a gel documentation system (Bio-Rad).
Statistical analysis
The differences in the distribution of age, gender and State of origin between the two study groups (C-HBV and SR) were assessed using either w 2 test or Student's t-test, as appropriate. The allelic and genotypic distributions were represented as simple frequencies and compared between the study groups using w 2 test (univariate analysis). Hardy-Weinberg equilibrium deviation was tested using w 2 test. The measures of linkage disequilibrium was calculated between all pairs of biallelic loci, namely, Lewontin's D 0 (|D|) and the r 2 measures using Haploview 4.1. 50 Haplotypes and their frequencies were inferred using an accelerated expectation maximization algorithm similar to the partition/ ligation method described earlier using Haploview 4.1 (see ref. 51 ) Multivariable logistic regression analyses were performed for each of the three genetic models (codominant, dominant and recessive) to estimate the independent effect of polymorphisms on disease phenotypes, after adjusting for the effects of age (as a continuous variable) and sex (male ¼ 0, female ¼ 1). ORs with 95% CIs were obtained. To adjust for multiple testing, Bonferroni correction was applied based on the number of single-nucleotide polymorphisms analyzed for TNF polymorphisms and the significance level was kept at 0.01. This correction was also applied for HLA polymorphisms based on the number of alleles analyzed and the significance levels were kept at 0.005 for HLAclass I (A), 0.004 for class I (B), 0.006 for class II (DR) and 0.01 for class II (DQ). Permutation test was used and empirical P-values for TNF polymorphisms were calculated by 10 000 permutations. 33 Statistical analysis was done using STATA 10 (Statacorp, College Station, TX, USA).
